ShowcasesPricing
  1. US-listed companies
  2. PRESSURE BIOSCIENCES INC

PRESSURE BIOSCIENCES INCPBIO

Market cap
$2.55M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
Net loss-3,450,205-4,084,427-4,612,540-7,415,298-2,706,984-10,715,561-9,699,318-11,660,917-16,005,543-20,153,486-16,076,678
Gain on loan forgiveness---------734,07710,000
Non-cash lease expense---------65,194113,470
Common stock and warrants issued for interest----------3
Depreciation and amortization107,51979,56365,71425,28817,9398,57694,271123,596127,301110,128119,788
Accretion of interest and amortization of debt discount-------1,517,394-1,353,483-5,436,863-6,738,802-1,777,863
Common stock and warrants issued for debt extension-----5,044185,452--795,089-3,575,878-130,279-2,331,398
Allowance for inventory reserve----------641,815
Stock-based compensation expense133,193136,796101,125208,989379,964406,427592,4771488,792254,615215,098
(Gain) loss on investment in equity securities----------3,662
Common stock and warrants issued for services-----31,0001-179,077794,562446,670
Accounts receivable-84,988-68,630124,387-158,766196,233-74,472267,982-245,428-98,17423,518140,628
Inventories-95,651-186,686113,876187,820-133,087111,97856,107-78,814-24,949554,787180,644
Prepaid expenses and other assets-20,099-4,33318,63115,72244,201-59,312-289,54442,815101,387107,681-165,090
Accounts payable----94,392-534,140182,01469,593156,908-43,819-226,771109,314
Accrued employee compensation-61,09929,9958,01418,66273,587119,10488,232-5,732-33,62215,10649,567
Operating lease liability----------65,194-113,470
Deferred revenue and other accrued expenses------442,1791413
Net cash used in operating activities-2,164,801-2,342,603-3,210,578-3,819,746-3,805,851-3,904,549-5,695,904-6,327,578-4,883,194-4,868,573-4,478,041
Purchases of property plant and equipment-58,7497,1399,4127,20321,825-23,3751,663122,94520,755
Net cash used in investing activities--58,749-7,139-9,412-7,203-171,825--23,375-796,663-122,945-20,755
Net proceeds from the issuance of Series AA Convertible Preferred Stock------33150,0001-
Sale of common stock377,453-149,165-530,965-----25,000
Proceeds from stock option exercises---------14,77317,443
Net proceeds from convertible debt11162267865
Net proceeds from non-convertible debt - third party---113231-3
Net proceeds from non-convertible debt - related party98,675222,000302,2526,300116,667-168,600259,500283,700254,600866,350
Payments on convertible debt101,556-350,000303,1003107,000925,54144322
Payments on non-convertible debt - related party--180,304416,69112,30020,000-103,600193,000199,200354,600315,300
Payments on non-convertible debt---587,949947,702222122
Net cash provided by financing activities22434466654
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS--------73,493-11,085113,771-128,446
Interest paid in cash-----533,53213764,600921,5691
Early ASU 2020-06 adoption----------473,027
Common stock issued with debt----------873,854
Discount from warrants issued with debt---------193,576
Common stock issued in lieu of cash for dividend---------184,274386,300
Preferred stock dividends---------22
Conversion of preferred stock for common stock----------44
Conversion of debt and interest into common stock---------3467,092
Discount due to beneficial conversion feature---------1-
Recognition of right of use asset and liability---------239,327-